Research has addressed the lack of response of MSS mCRC to pembrolizumab monotherapy, finding that adding maraviroc, an anti-HIV agent inhibiting C-C motif chemokine receptor 5 (CCR5), leads to an anti-tumor activation of macrophages. The gene discussed is CCR5; the disease is neoplasm.